Mylan: Allergan ’ s legal move with tribe reveals “ duplicitousness ” towards patent system

Allergan (NYSE:AGN) was dealt a major blow yesterday after a Texas judge ruled that claims to a number of patents for its dry eye drug, Restasis, were invalid due to obviousness. The ruling opens the door for generic versions of the drug that accounted for nearly 10% of Allergan’s revenue last year. The decision came in a suit involving generic drugmakers like Mylan (NSDQ:MYL), which celebrated the ruling as a push back against Allergan’s recent move to transfer its Restasis patents to a Native American tribe. Get the full story at our sister site, Drug Delivery Business News. The post Mylan: Allergan’s legal move with tribe reveals “duplicitousness” towards patent system appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Legal News Patent Infringement Pharmaceuticals Wall Street Beat Allergan Inc. Mylan Source Type: news